• Nycomed US Inc., of Melville, N.Y., appointed Joseph J. LaRosa senior vice president and general counsel.

• OctoPlus NV, of Leiden, the Netherlands, named Jan Hendrik Egberts and nominated him for appointment as CEO.

• Omeros Corp., of Seattle, appointed Kenneth M. Ferguson vice president of development.

• OncoGenex Pharmaceuticals Inc., of Bothell, Wash., appointed Michelle Burris executive vice president of operations and chief financial officer.

• On-Q-ity, of Waltham, Mass., appointed Walter Carney chief scientific officer.

• Optimer Pharmaceuticals Inc., of San Diego, named Kurt Hartman general counsel and access.

• Optivia Biotechnology Inc., of Menlo Park, Calif., appointed Yuichi Sugiyama to its scientific advisory board.

• Otonomy Inc., of San Diego, named David A. Weber president, CEO and board member.

• Palatin Technologies Inc., of Cranbury, N.J., appointed Jeffrey D. Edelson chief medical officer.

• PolyMedix Inc., of Radnor, Pa., expanded its scientific advisory team with the additions of William F. DeGrado, Gregory N. Tew, Gill Diamond, Henry S. Heine and William J. Weiss. It also named Helen W. Boucher, John Bradley, G. Ralph Corey, Stanley Deresinski, Alasdair MacGowan and Brad Spellberg to its infectious disease clinical advisory board chaired by Roger M. Echols.

• PolyTherics Ltd., of London, appointed John Burt chief business officer.

• Probiodrug AG, of Halle, Germany, appointed Cynthia Lemere to its scientific advisory board.

• Prolong Pharmaceuticals Inc., of South Plainfield, N.J., added Richard Prince as vice president of quality and Andy Burger as vice president of information services.

• Protox Therapeutics Inc., of Vancouver, British Columbia, named Lars Ekman chairman and added Jonathan Leff and Nishan de Silva to the board.